Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atherosclerosis
Lilly pays $1.6 million with initiation of phase 2 trial on athersclerosis drug
August 11th, 2005
Ligand Pharmaceuticals Incorporated (LGNDE) has earned a $1.6 million milestone payment from Eli Lilly and company (LLY) with Lilly's initiation of phase 2 studies on LY674, a novel peroxisome proliferation activated receptor (PPAR) modulator for the treatment of atherosclerosis. LY674 was discovered pursuant to the research collaboration agreement between Lilly and Ligand. Atherosclerosis is the hardening and narrowing of the arteries caused by the slow buildup of plaque on the inside of walls of the arteries. According to the U.S. National Institutes of Health, diseases caused by atherosclerosis, including peripheral arterial disease, angina, heart attack, and stroke,...
Source: Women's Health Weekly (2005-08-11)
|
